Supplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors

Authors: Edward Favours, Haiying Tang, Peyton Wong et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Efficacy testing summary results for Wilms tumor models treated with vobra duo and SYD988.Treatment groups: A = control, B = vobra duo: 6 mg/kg, IP, Day 0 × 1, C=SYD988: 6 mg/kg, IP, Day 0 × 1.</p></jats:p>

Keywords

vobra mgkg pefficacy testing summary

Supplementary Table S7 from Preclinical Activity of the B7-H3–Targeting Antibody–Drug Conjugate Vobramitamab Duocarmazine in Pediatric Solid Tumors

Abstract

Keywords

Related Articles

Deep Learning for Saffron Adulteration Detection from Stigma Images: A Comparative Study of AlexNet, ResNet, and VGG16

‘Narcissist’ bosses are more likely to oppose work from home, studies show. But are they right?

On the Impossibility of Deriving Quantitative Intra-Multiplet Splittings from Symmetry-Complete Dynamics Alone

Regulatory Failure, Device Recall, and Re-Entry Approval: A Global Perspective from the Breast Implant Industry (Preprint)

Learning from Alcohol Rewards: Neural Signatures of Drug-Related Reward Prediction Errors in Alcohol Use Disorder